178 related articles for article (PubMed ID: 22726551)
1. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
Moran E; Carbone F; Augusti V; Patrone F; Ballestrero A; Nencioni A
Semin Hematol; 2012 Jul; 49(3):270-6. PubMed ID: 22726551
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
Liang Y; Liu H
Curr Pharm Des; 2013; 19(18):3299-304. PubMed ID: 23151133
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition for antibody-mediated rejection.
Everly JJ; Walsh RC; Alloway RR; Woodle ES
Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition for antibody-mediated allograft rejection.
Sadaka B; Alloway RR; Shields AR; Schmidt NM; Woodle ES
Semin Hematol; 2012 Jul; 49(3):263-9. PubMed ID: 22726550
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib is effective to treat acute humoral rejection after liver transplantation.
Lee CF; Eldeen FZ; Chan KM; Wu TH; Soong RS; Wu TJ; Chou HS; Lee WC
Transplant Proc; 2012 Mar; 44(2):529-31. PubMed ID: 22410063
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation.
Baum C; Reichenspurner H; Deuse T
J Heart Lung Transplant; 2013 Dec; 32(12):1270-1. PubMed ID: 24041981
[No Abstract] [Full Text] [Related]
8. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
10. Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient.
Claes DJ; Yin H; Goebel J
Pediatr Transplant; 2014 Jun; 18(4):E100-5. PubMed ID: 24725066
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor therapy for antibody-mediated rejection.
Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
[TBL] [Abstract][Full Text] [Related]
12. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
[TBL] [Abstract][Full Text] [Related]
13. Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
Manitpisitkul W; Wilson NS; Philosophe B; Cooper M; Drachenberg C; Kukuruga D; Nogueira J; Haririan A
Clin Transpl; 2010; ():421-8. PubMed ID: 21698839
[No Abstract] [Full Text] [Related]
14. Proteasome inhibitors: antitumor effects and beyond.
Nencioni A; Grünebach F; Patrone F; Ballestrero A; Brossart P
Leukemia; 2007 Jan; 21(1):30-6. PubMed ID: 17096016
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
Cooper JE; Wiseman AC; Chan L
Clin Transpl; 2010; ():415-20. PubMed ID: 21698838
[No Abstract] [Full Text] [Related]
16. [Development and clinical application of novel proteasome inhibitors].
Iida S
Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
[No Abstract] [Full Text] [Related]
17. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
18. Clinical and investigational use of proteasome inhibitors for transplant rejection.
Sadaka B; Alloway RR; Woodle ES
Expert Opin Investig Drugs; 2011 Nov; 20(11):1535-42. PubMed ID: 21916809
[TBL] [Abstract][Full Text] [Related]
19. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
Gomez AM; Willcox N; Molenaar PC; Buurman W; Martinez-Martinez P; De Baets MH; Losen M
Ann N Y Acad Sci; 2012 Dec; 1274():48-59. PubMed ID: 23252897
[TBL] [Abstract][Full Text] [Related]
20. Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
Lubetzky M; Auli MJ; Walker J; Leeser D; Kapur S; Hartono C; Dadhania D
Clin Transpl; 2010; ():437-40. PubMed ID: 21696061
[No Abstract] [Full Text] [Related]
[Next] [New Search]